quality control review & editing services
Delivering an unparalleled attention to detail
Detailed and comprehensive quality control (QC) reviews (or data verification reviews) and editing are an integral part of the production lifecycle of a document, rather than a one-off step in the development process. Mistakes and inconsistencies in a document can call into question the validity of the content or result in an incorrect interpretation of the data.
ProPharma’s team of seasoned QC reviewers/editors provides quality review and editing services across a wide array of documents and therapeutic areas.
Ready to Speak to a Quality Control Reviewer/Editor?
Quality Control Review/Editing Services
ProPharma QC reviewers/editors perform targeted or comprehensive quality control reviews of documents to ensure accuracy, integrity, and consistency of both data and messaging.
Quality control reviews and/or editorial reviews are performed on any deliverable, in any therapeutic area, using either client checklists or our internal document-specific checklists to ensure the quality and consistency both within and across documents.
Quality Control Review:
Data Verification
ProPharma QC reviewers/editors provide 100% source verification of all data in both document text and in-text tables, as necessary. Data verification review is offered in addition to editorial review or as a standalone service.
Editorial Review:
No Data Verification
ProPharma QC reviewers/editors provide a complete editorial review to ensure consistency, clarity of message, and appropriate implementation of style and template requirements. Editorial review includes general copy editing and review of abbreviations, internal cross references, and citations, and is offered in addition to data verification review or as a standalone service.
Benefits of Working with Our Quality Control Review/Editing Team
GLOBAL AND EXPERIENCED
ProPharma QC reviewers/editors are located across North America, Europe, and India. They have an average of 10 years of experience spanning multiple therapy areas and domains.
FLEXIBLE AND SCALABLE
With access to a large pool of experienced resources, we are responsive to changes in workload and can scale as needed to accommodate variable client demands and volume.
COMPREHENSIVE AND THOROUGH
We perform comprehensive reviews of each document using detailed document-specific checklists to ensure quality and consistency within and across documents.
Quality Control Review Frequently Asked Questions
Click on frequently asked questions about ProPharma's quality control review and editing services to learn about our experience and expertise.
Yes, ProPharma QC reviewers/editors accommodate last-minute and drop-in QC requests as needed.
ProPharma understands that timelines shift, projects get cancelled, and that shifting timelines are a potential risk in any project. ProPharma remains flexible and mitigates this risk through consistent project and resource management. Resource availability and project status are routinely reviewed and updated, allowing us to adapt in real time and overcome any potential challenges, including timeline shifts.
If a project shifts out significantly, we work with clients to map out a plan that ensures both timely delivery and service continuity. We take steps to ensure (to the extent possible) the same person can re-engage on the project once it becomes active again. If timelines accelerate, we can provide additional resources, as needed, to ensure timeline integrity.
ProPharma can utilize either our internal QC SOPs or client SOPs.
Yes. ProPharma has both general and document-specific QC checklists.
Yes, ProPharma QC reviewers/editors provide consistent application of general and/or client-specific style guides (including therapeutic area-specific style guides, as applicable).
Have questions? We'd be happy to talk with you
about your unique needs and goals.
News & Insights
May 19, 2026
Rethinking Biometrics Resourcing in Modern Clinical Trials
Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.
May 18, 2026
The Hidden Value of Medical Information: Strengthening Brand Trust
Discover how Medical Information strengthens brand trust in the pharmaceutical industry by providing reliable, unbiased, and timely support for patients and healthcare professionals.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
December 11, 2025
ProPharma Expands Operations with New Office in Hyderabad
ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...